
RDY
Dr. Reddy'S Laboratories
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 2
Consensus Rating "Strong Buy"
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Bearish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RDY
Dr. Reddy'S Laboratories Limited
An Indian developer of active pharmaceutical ingredients, intermediates, and finished dosage forms
Pharmaceutical
02/24/1984
04/11/2001
New York Stock Exchange
27,811
03-31
Depository Receipts (Ordinary Shares)
8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India
--
Dr. Reddy'S Laboratories Limited, established on February 24, 1984, is an integrated global pharmaceutical company dedicated to providing new drugs at affordable prices through its three core business divisions: Global Generics Division, Pharmaceutical Services and Active Ingredients Division (PSAI) and Proprietary Products Division. Its global branded and unbranded generic drug segment includes prescription and over-the-counter (OTC) drug operations. The company's Pharmaceutical Services and Active Ingredients Division (PSAI) consists of the Pharmaceutical Ingredients (API) business and customized pharmaceutical services. The company's patented product section consists of biopharmaceutical companies, new chemical entity business, differentiated formulation business and dermatological professional business key enterprises operated by promius pharmaceutical company.
Company Financials
EPS
RDY has released its 2025 Q4 earnings. EPS was reported at 0.22, versus the expected 0.1859523258457, beating expectations. The chart below visualizes how RDY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RDY has released its 2025 Q4 earnings report, with revenue of 995.67M, reflecting a YoY change of 17.15%, and net profit of 185.80M, showing a YoY change of 18.47%. The Sankey diagram below clearly presents RDY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available